Skip to main content
. 2016 Jan 2;10(5):719–734. doi: 10.1016/j.molonc.2015.12.013

Figure 4.

Figure 4

Combined mel‐flufen and gemcitabine or cisplatin treatment decreases cell survival in UC cells. (A) Left: J82 cells were treated with either mel‐flufen (0.1 or 0.5 μM), gemcitabine (0.025 μM), or a combination, during 1 h and post incubated for 72 h. The number of cells were counted using Trypan blue and is presented as % of untreated control. Data shown is the mean ± SD of three experiments. Student's t‐test was used to achieve the indicated P‐values. Right: PARP‐1 cleavage was examined in J82 cells after mel‐flufen, gemcitabine, and combined treatment. GAPDH was used as loading control. Fold ratio CL/FL PARP was determined by densitometry. (B) Left: J82 cells were treated with either mel‐flufen (0.1 μM) or cisplatin (1 μM) for 1 h and post incubated for another 48 h and counted as in (A). Right: PARP‐1 cleavage was examined in J82 cells after mel‐flufen, cisplatin, and their combination. GAPDH was used as loading control.